ARC logo.png
Ear Infection Treatment Market Value Projected To Reach US$ 9.6 Billion By 2028 Covering Covid-19 Impact: Acumen Research and Consulting
August 05, 2021 11:10 ET | Acumen Research and Consulting
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Ear Infection Treatment Market– Global Industry Analysis, Market Size,...
ARC logo.png
Ear Nose and Throat (ENT) Treatment Market Value Surpass To Reach US$ 30.2 Billion By 2028 Covering Covid-19 Analysis: Acumen Research and Consulting
August 03, 2021 10:20 ET | Acumen Research and Consulting
LOS ANGELES, Aug. 03, 2021 (GLOBE NEWSWIRE) -- The Global Ear, Nose, and Throat (ENT) Treatment Market is expected to grow at a CAGR of around 5.5% from 2021 to 2028 and expected to reach around US$...
Cross Keys Capital Advises Atlanta Allergy & Asthma Clinic on Partnership with Southern Ear, Nose, Throat & Allergy Partners
September 30, 2020 17:59 ET | Cross Keys Capital, LLC.
Fort Lauderdale, Florida, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Cross Keys Capital served as the exclusive M&A advisor to Atlanta Allergy & Asthma Clinic ("Atlanta Allergy") in its partnership...
lyra logo.jpg
Lyra Therapeutics Presents Clinical Data Demonstrating LYR-210’s Local Anti Inflammatory Effects for the Treatment of Chronic Rhinosinusitis
September 10, 2020 18:00 ET | Lyra Therapeutics
Two additional presentations highlight supporting data for LYR-210’s clinical program covering key clinical endpoints for CRS and Lyra’s XTreo™ drug release performance Findings presented at the...
lyra logo.jpg
Lyra Therapeutics to Present Data Supporting LYR-210 for the Treatment of Chronic Rhinosinusitis
September 03, 2020 16:05 ET | Lyra Therapeutics
WATERTOWN, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel...
lyra logo.jpg
Lyra Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 05, 2020 16:05 ET | Lyra Therapeutics
- On track to report topline Phase 2 results for LYR-210 in chronic rhinosinusitis in 4Q 2020 - - Conference call and webcast today at 4:30 p.m. ET - WATERTOWN, Mass., Aug. 05, 2020 (GLOBE...
lyra logo.jpg
Lyra Therapeutics to Present at the BTIG Virtual Biotechnology Conference
August 04, 2020 16:05 ET | Lyra Therapeutics
WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
lyra logo.jpg
Lyra Therapeutics Announces Pamela Nelson as Senior Vice President of Regulatory Affairs
August 04, 2020 08:00 ET | Lyra Therapeutics
WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
lyra logo.jpg
Lyra Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference
July 30, 2020 16:05 ET | Lyra Therapeutics
WATERTOWN, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
lyra logo.jpg
Lyra Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update
July 24, 2020 08:30 ET | Lyra Therapeutics
WATERTOWN, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...